Evolution of dry powder inhaler design, formulation, and performance.

Many companies are now prioritizing the development of dry powder inhalers (DPIs) above pressurized formulations of asthma drugs. A well-designed DPI and an appropriate powder formulation can optimize the effectiveness of inhaled drug therapy. A DPI must be able to deliver medications effectively for most patients, and an ideal inhaler would provide a dose that does not vary with inspiratory flow rate. Recent regulatory guidelines, among which the U.S. FDA draft guidance is the most stringent, demand consistent dose delivery from an inhaler throughout its life and consistency of doses from one inhaler to another. However, the properties of free micronized powders often interfere with drug handling and with drug delivery reducing dose consistency. Recent advances in formulation technology can increase lung dose and reduce its variability. While a perfect DPI may never exist, both device and formulation technology are evolving to rectify perceived deficiencies in earlier systems.

[1]  J. H. Bell,et al.  Dry powder aerosols. I. A new powder inhalation device. , 1971, Journal of Pharmacy and Science.

[2]  G. Hallworth.  AN IMPROVED DESIGN OF POWDER INHALER , 1977 .

[3]  M Lippmann,et al.  Deposition, retention, and clearance of inhaled particles. , 1980, British journal of industrial medicine.

[4]  F. Morén.  Pressurized aerosols for oral inhalation , 1981 .

[5]  T. Clark,et al.  The importance of particle size in response to inhaled bronchodilators. , 1982, European journal of respiratory diseases. Supplement.

[6]  J. Kh,et al.  Advances in Pharmaceutical Sciences , 1982 .

[7]  J. Baskerville,et al.  Use of spacers to facilitate inhaled corticosteroid treatment of asthma. , 2015, The American review of respiratory disease.

[8]  D. Pavia,et al.  Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects. , 1986, Thorax.

[9]  P. Paronen,et al.  Effect of powder inhaler design on drug deposition in the respiratory tract , 1988 .

[10]  G. Persson,et al.  The bronchodilator response from inhaled terbutaline is influenced by the mass of small particles: a study on a dry powder inhaler (Turbuhaler). , 1989, The European respiratory journal.

[11]  S. Clarke,et al.  Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. , 1989, The European respiratory journal.

[12]  H. Chrystyn,et al.  Determination of the relative bioavailability of salbutamol to the lung following inhalation. , 1992, British journal of clinical pharmacology.

[13]  S. Spiro,et al.  Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. , 1993, Thorax.

[14]  B. Lipworth,et al.  Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device. , 1993, British journal of clinical pharmacology.

[15]  S. Newman,et al.  Scintigraphic assessment of therapeutic aerosols. , 1993, Critical reviews in therapeutic drug carrier systems.

[16]  A. Hollingworth,et al.  The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers--implications for in vitro testing. , 1993, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[17]  J. Ayres,et al.  Incidence of acute decreases in peak expiratory flow following the use of metered-dose inhalers in asthmatic patients. , 1994, The European respiratory journal.

[18]  P. Ventura,et al.  A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates , 1994 .

[19]  S. Newman,et al.  Effect of different modes of inhalation on drug delivery from a dry powder inhaler , 1994 .

[20]  M. Partridge.  Metered-dose inhalers and CFCs: what respiratory physicians need to know. , 1994, Respiratory medicine.

[21]  L. Borgström,et al.  Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. , 1994, The European respiratory journal.

[22]  I. Amirav,et al.  What do pediatricians in training know about the correct use of inhalers and spacer devices? , 1994, The Journal of allergy and clinical immunology.

[23]  A. R. Clark,et al.  Medical Aerosol Inhalers: Past, Present, and Future , 1995 .

[24]  Peter R. Byron,et al.  Dose emissions from marketed dry powder inhalers , 1995 .

[25]  P. Korhonen,et al.  Easyhaler® Multiple Dose Powder Inhaler—Practical and Effective Alternative to the Pressurized MDI , 1995 .

[26]  M. Newhouse,et al.  Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. , 1996, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[27]  R. Pauwels,et al.  The inhalation device influences lung deposition and bronchodilating effect of terbutaline. , 1996, American journal of respiratory and critical care medicine.

[28]  E. Israel,et al.  Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. , 1996, American journal of respiratory and critical care medicine.

[29]  P. Hagedoorn,et al.  Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers part 2: effect of peak flow rate (pifr) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers , 1996 .

[30]  Newman,et al.  A scintigraphic study to evaluate the deposition patterns of a novel anti-asthma drug inhaled from the Cyclohaler dry powder inhaler. , 1997, Advanced drug delivery reviews.

[31]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[32]  M. Everard,et al.  Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. , 1997, Respiratory medicine.

[33]  S. Newman,et al.  Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler. , 1997, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[34]  H. Chrystyn.  Is total particle dose more important than particle distribution? , 1997, Respiratory medicine.

[35]  R. Pauwels,et al.  Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. , 1997, The European respiratory journal.

[36]  L. Okamoto,et al.  Importance of selected inhaler characteristics and acceptance of a new breath-actuated powder inhalation device. , 1997, The Journal of asthma : official journal of the Association for the Care of Asthma.

[37]  G. P. Martin,et al.  On the relationship between drug and carrier deposition from dry powder inhalers in vitro , 1998 .

[38]  S. P. Newman.  Scintigraphic assessment of pulmonary delivery systems , 1998 .

[39]  Hans Bisgaard.  Automatic actuation of a dry powder inhaler into a nonelectrostatic spacer. , 1998, American journal of respiratory and critical care medicine.

[40]  R. Langer,et al.  Recent advances in pulmonary drug delivery using large, porous inhaled particles. , 1998, Journal of applied physiology.

[41]  G. Rowley,et al.  Measurement of electrostatic charge decay in pharmaceutical powders and polymer materials used in dry powder inhaler devices. , 1998, Drug development and industrial pharmacy.

[42]  E. Bondesson,et al.  Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma. , 1998, Respiratory medicine.

[43]  M. Newhouse,et al.  Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. , 1999, Chest.

[44]  R Horne,et al.  Compliance in asthma. , 1999, Respiratory medicine.

[45]  York,et al.  Strategies for particle design using supercritical fluid technologies. , 1999, Pharmaceutical science & technology today.

[46]  M. Bala,et al.  Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. , 2000, Chest.

[47]  M. Everard.  CFC transition: the Emperor's new clothes. Each class of drug deserves a delivery system that meets its own requirements , 2000, Thorax.

[48]  Sumby,et al.  Latest advances in the development of dry powder inhalers. , 2000, Pharmaceutical science & technology today.

[49]  L. Fabbri,et al.  Improving patient compliance with asthma therapy. , 2000, Respiratory medicine.

[50]  R. Hermann,et al.  Scintigraphic comparison of budesonide deposition from two dry powder inhalers. , 2000, The European respiratory journal.

[51]  E. Schenkel,et al.  46 Airflow profiles and inhaler technique with the new mometasone furoate dry powder inhaler (MF-DPI) , 2000 .

[52]  G. Crompton,et al.  Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. , 2000, Respiratory medicine.

[53]  K. Nolop,et al.  Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[54]  T Lankinen,et al.  Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. , 2000, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[55]  V M Chinchilli,et al.  The Asthma Clinical Research Network. , 2001, Controlled clinical trials.

[56]  P. Burnell,et al.  Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. , 2001, Respiratory medicine.

[57]  John N. Staniforth,et al.  Aerosol Electrostatics I: Properties of Fine Powders Before and After Aerosolization by Dry Powder Inhalers , 2004, Pharmaceutical Research.

[58]  Kjell Wetterlin,et al.  Turbuhaler: A New Powder Inhaler for Administration of Drugs to the Airways , 1988, Pharmaceutical Research.

[59]  L. Borgström,et al.  A Method for Determination of the Absolute Pulmonary Bioavailability of Inhaled Drugs: Terbutaline , 1990, Pharmaceutical Research.

[60]  John N. Staniforth,et al.  Enhancement of Small Particle Size Dry Powder Aerosol Formulations using an Ultra Low Density Additive , 1999, Pharmaceutical Research.

[61]  A. Bot,et al.  Novel Lipid-Based Hollow-Porous Microparticles as a Platform for Immunoglobulin Delivery to the Respiratory Tract , 2000, Pharmaceutical Research.